Literature DB >> 19608616

Third consensus on medical treatment of metastatic breast cancer.

S Beslija1, J Bonneterre, H J Burstein, V Cocquyt, M Gnant, V Heinemann, J Jassem, W J Köstler, M Krainer, S Menard, T Petit, L Petruzelka, K Possinger, P Schmid, E Stadtmauer, M Stockler, S Van Belle, C Vogel, N Wilcken, C Wiltschke, C C Zielinski, H Zwierzina.   

Abstract

BACKGROUND: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures.
DESIGN: To provide timely and evidence-based recommendations for the diagnostic workup and treatment of patients with MBC, an international expert panel reviewed and discussed the evidence available from clinical trials regarding diagnostic, therapeutic and supportive measures with emphasis on their impact on the quality of life and overall survival of patients with MBC.
RESULTS: Evidence-based recommendations for the diagnostic workup, endocrine therapy, chemotherapy, use of targeted therapies and bisphosphonates, surgical treatment and supportive care measures in the management of patients with MBC were formulated.
CONCLUSIONS: The present consensus manuscript updates evidence-based recommendations for state-of-the-art treatment of MBC depending on disease-associated and biological variables.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608616     DOI: 10.1093/annonc/mdp261

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  48 in total

1.  Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

Authors:  Nina Mortazavi-Jehanno; Anne-Laure Giraudet; Laurence Champion; Florence Lerebours; Elise Le Stanc; Veronique Edeline; Olivier Madar; Dominique Bellet; Alain Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

Review 2.  Triple-negative breast cancer.

Authors:  Rupert Bartsch; Reinhard Ziebermayr; Christoph C Zielinski; Guenther G Steger
Journal:  Wien Med Wochenschr       Date:  2010-04

Review 3.  Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

Authors:  Patricia Gomez; Mario E Lacouture
Journal:  Oncologist       Date:  2011-10-20

Review 4.  Symptom management in metastatic breast cancer.

Authors:  William Irvin; Hyman B Muss; Deborah K Mayer
Journal:  Oncologist       Date:  2011-08-31

5.  Eribulin mesylate.

Authors:  Timothy K Huyck; William Gradishar; Fil Manuguid; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

6.  Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.

Authors:  Sayyed Farshid Moussavi-Harami; Kari B Wisinski; David J Beebe
Journal:  J Patient Cent Res Rev       Date:  2014

Review 7.  Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Authors:  Olivier Humbert; Alexandre Cochet; Bruno Coudert; Alina Berriolo-Riedinger; Salim Kanoun; François Brunotte; Pierre Fumoleau
Journal:  Oncologist       Date:  2015-01-05

Review 8.  The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

Authors:  Mustafa Khasraw; Edi Brogi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

9.  Radiofrequency ablation of metastatic lesions from breast cancer.

Authors:  C Bortolotto; S Macchi; L Veronese; R Dore; F Draghi; S Rossi
Journal:  J Ultrasound       Date:  2012-06-27

10.  Aggressive treatment for hepatic metastases from breast cancer: results from a single center.

Authors:  F Polistina; G Costantin; A Febbraro; E Robusto; G Ambrosino
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.